Matinas BioPharma : Investor Presentat

Corporate Presentation

December 2020

1

Forward-Looking Statement	MTNB

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K,10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

2

Matinas Company Overview	MTNB

MAT9001

Potential Best-in-ClassOmega-3 Drug

• Potential best-in-class drug focused on severe hypertriglyceridemia with potential expansion into multi- billion-dollar market
• Head-to-headdata demonstrating superior triglyceride lowering and EPA levels against leading drug, Vascepa®
• Key additional head to head data upcoming from ENHANCE-IT study vs. Vascepa
• Clear differentiation from currently approved prescription omega-3 products

3

LNC PLATFORM

Lipid Nano-Crystal Delivery System

• Safe, oral, targeted intracellular delivery of potent medicines
• MAT2203: Oral Amphotericin B, a broad-spectrum antifungal agent. Program financially supported by the National Institutes of Health
• EnACT study for MAT2203 in cryptococcal meningitis represents gateway opportunity for the treatment of invasive fungal infections. Currently enrolling Cohort 2
• Feasibility evaluations with three Big Pharma companies across multiple compounds

3

Key Milestones Support Investment Thesis	MTNB

MAT9001

Potential Best-in-ClassOmega-3 Drug

• August 2020: Fully enrolled ENHANCE-IT study
• Q3 2020: End-of-Phase 2 meeting with FDA

• Q1 2021: Top-line data from ENHANCE-IT study
• H1 2021: Commence Phase 3 in severe hypertriglyceridemia

LNC PLATFORM

Lipid Nano-Crystal Delivery System

• Q3 2020: Phase 2 EnACT study - Cohort 1 completed
• Unanimous DSMB approval to move to Cohort 2 following review of Cohort 1 safety and efficacy data
• H2 2020: MAT2501 grant decision from CF Foundation

• Enrolling EnACT Cohort 2. Next update mid-2021
• LNC platform collaboration updates

$50M+ equity financing in January 2020 extends cash runway for 2+ years,

through multiple data read-outs and catalysts.

4

4